Illustration of a microscope, three test tubes in a wooden rack, and three bottles with yellowish liquid, all set against a soft, abstract background.

The Drug Development Pipeline

Home / Celiac Disease Research / Drug Development / Drug Development Pipeline

Drug Development Pipeline

Did you know that researchers are currently developing drugs to treat celiac disease? One day, our community may have a pill to defend against cross-contact, an injection to prevent the immune system from attacking the small intestine, or even a treatment to replace the gluten-free diet entirely.

If that sounds exciting to you, be sure to bookmark this page and subscribe to our research newsletter, where we update you with any changes to the celiac disease drug development scene.

The process of developing a treatment and getting it to market is long and fraught with challenges. About 90% of all drugs in clinical trials never make it to market (although it’s closer to 85% for autoimmune conditions specifically!). But we firmly believe that it’s only a matter of time before our community has a treatment beyond the gluten-free diet. Learn how we’re accelerating the process. And to learn about the phases of drug development, download our Clinical Trials infographic.

Want to get involved? Consider joining a clinical trial! See if there are any active clinical trials near you.

Drugs to Treat Celiac Disease by Therapeutic Approach

Last updated 9/14/26

A chart lists three gluten-related therapeutic approaches, each with phase columns and treatments filled in, such as IMGX-003, E40, IMU-856, TPM502, MTX-101, and VTP-100.
A chart titled The Drug Development Pipeline lists drugs in clinical phases for celiac disease, organized by mechanism: preventing tTG modifying gluten and interrupting the immune reaction. Updated September 14, 2026.